-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $412

Benzinga·02/27/2026 17:35:17
Listen to the news
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $400 to $412.